Disclose the method for inhibiting tumor development in object. This method includes the nucleic acid of dominant negative tumor necrosis factor (the DN-TNF)-α albumen and/or encoding D N-TNF- α albumen to object application therapeutically effective amount. The nucleic acid of DN-TNF- α albumen and/or encoding D N-TNF- α albumen can be administered alone or apply with other pharmaceutical agent combinations.